Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta‐Analysis of Randomized Clinical Trials

Dapagliflozin and empagliflozin versus placebo for cardiovascular death or worsening heart failure across the ejection-fraction spectrum: a systematic review and meta-analysis of randomized placebo-controlled trials

Background and aims: Dapagliflozin and empagliflozin are established therapy for chronic heart failure across the ejection-fraction spectrum. Their pivotal trials were powered for a composite of cardiovascular death and worsening heart failure

Impact of Semaglutide, Liraglutide and Tirzepatide on Cardiometabolic Outcomes: A Comparative Narrative Review

Cardiometabolic disorders such as type 2 diabetes mellitus (T2DM), obesity and cardiovascular disease (CVD) remain major global health challenges. Incretin‐based therapies, including the GLP‐1 receptor agonists semaglutide and liraglutide, and the dual GIP/GLP‐1 receptor agonist tirzepatide, are increasingly used to ad...

Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST‐T1D Extension Study

To evaluate changes in glycaemic control following semaglutide discontinuation in adults with Type 1 diabetes and obesity who completed the ADJUST‐T1D randomised controlled trial.

Response to Letters to the Editor Regarding ‘Role of Evogliptin for Intra‐Class Therapeutic Interchange in Patients With Type 2 Diabetes Mellitus: Subgroup Analysis From a Multi‐Center, Prospective, Observational Study (REVISE Study)’

of Evogliptin for Intra-Class Therapeutic Interchange in Patients With Type 2 Diabetes Mellitus: Subgroup Analysis From a Multi-Center, Prospective, Observational Study (REVISE Study)”

EMPAGLIFLOZIN AND DAPAGLIFLOZIN IN IMPROVING EJECTION FRACTION: A PROSPECTIVE OBSERVATIONAL COMPARISON OF CLINICAL OUTCOMES AND PATIENT REPORTED QUALITY OF LIFE

Background: SGLT2 inhibitors have transformed heart failure treatment, especially empagliflozin and dapagliflozin. Although both have proven cardiovascular benefits in clinical trials, there is little data comparing them in real-world settings. This study aims to address that by comparing their effects on heart functio...

Efficacy and Safety of Ticagrelor and Aspirin in Patients With Moderate Ischemic Stroke An Exploratory Analysis of the THALES Randomized Clinical Trial